CD4+ invariant natural killer T cells protect from murine GVHD lethality through expansion of donor CD4+CD25+FoxP3+ regulatory T cells-Reference-Cited by-同舟云学术

CD4+ invariant natural killer T cells protect from murine GVHD lethality through expansion of donor CD4+CD25+FoxP3+ regulatory T cells

Published:2014-11-20 Issue:22 Volume:124 Page:3320-3328
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Schneidawind Dominik¹,Pierini Antonio¹,Alvarez Maite¹,Pan Yuqiong¹,Baker Jeanette¹,Buechele Corina²,Luong Richard H.³,Meyer Everett H.¹,Negrin Robert S.¹

Affiliation:

1. Division of Blood and Marrow Transplantation, Department of Medicine,

2. Department of Pathology, and

3. Department of Comparative Medicine, Stanford University, Stanford, CA

Abstract

Key Points Low doses of adoptively transferred donor CD4+ iNKT cells protect from GVHD while preserving graft-versus-tumor effects. Donor CD4+ iNKT cells inhibit proliferation of alloreactive T cells and promote robust expansion of donor Tregs.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/124/22/3320/1465288/3320.pdf

Reference36 articles.

1. Graft-versus-host disease.;Ferrara;N Engl J Med,1991

2. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation.;Edinger;Nat Med,2003

3. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation.;Di Ianni;Blood,2011

4. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics.;Brunstein;Blood,2011

5. Regulatory T cells and natural killer T cells for modulation of GVHD following allogeneic hematopoietic cell transplantation.;Schneidawind;Blood,2013

Cited by 92 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Allogeneic “Off-the-Shelf” CAR T cells: Challenges and advances;Best Practice & Research Clinical Haematology;2024-09

2. Traversing the bench to bedside journey for iNKT cell therapies;Frontiers in Immunology;2024-08-07

3. CD19-chimeric antigen receptor-invariant natural killer T cells transactivate NK cells and reduce alloreactivity;Cytotherapy;2024-08

4. Human CD4⁺iNKT cell adoptive immunotherapy induces anti‐tumour responses against CD1d‐negative EBV‐driven B lymphoma;Immunology;2024-05-13

5. invariant Natural Killer T cell therapy as a novel therapeutic approach in hematological malignancies;Frontiers in Transplantation;2024-05-06